Jinyu Li

Jinyu Li


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2025 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
MHMeiru Han
Meiru Han
HXHuan Xia
Huan Xia
GXGuiyang Xia
Guiyang Xia
XWXiaohong Wei
Xiaohong Wei
JLJinyu Li
Jinyu Li
SLSheng Lin
Sheng Lin

18 October 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DFDirk Fahrenkamp
Dirk Fahrenkamp
JLJinyu Li
Jinyu Li
SESabrina Ernst
Sabrina Ernst
HLHildegard Schmitz-Van de Leur
Hildegard Schmitz-Van de Leur
NCNicolas Chatain
Nicolas Chatain
GMGerhard Müller-Newen
Gerhard Müller-Newen
STAT5 is an essential transcription factor in hematopoiesis, which is activated through tyrosine phosphorylation in response to cytokine stimulation. Constitutive activation of STAT5 is a hallmark of myeloid and lymphoblastic leukemia. Using homology modeling and molecular dynamics simulations, a model of the STAT5 phosphotyrosine-SH2 domain interface was generated providing first structural information on the activated STAT5 dimer including a sequence, for which no structural information is available for any of the STAT proteins. We identified a novel intramolecular interaction mediated through F706, adjacent to the phosphotyrosine motif, and a unique hydrophobic interface on the surface of the SH2 domain. Analysis of corresponding STAT5 mutants revealed that this interaction is dispensable for Epo receptor-mediated phosphorylation of STAT5 but essential for dimer formation and subsequent nuclear accumulation. Moreover, the herein presented model clarifies molecular mechanisms of recently discovered leukemic STAT5 mutants and will help to guide future drug development.

5 January 2017 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
JLJinyu Li
Jinyu Li
YWYi Wei
Yi Wei
XLXue Li
Xue Li
DZDashuai Zhu
Dashuai Zhu
BNBo Nie
Bo Nie
LCLimin Chai
Limin Chai
Xian-Fang-Huo-Ming-Yin (XFHM), a traditional herbal formula, has been used to treat sores and carbuncles for hundreds of years in Asia. Nowadays, its clinical effects in treatment of rheumatoid arthritis (RA) have been validated. In this study, we want to study its possible molecular mechanisms of regulating the differentiation of lymphocytes and production of pro-inflammatory cytokines in collagen-induced arthritis (CIA) mice for RA treatment. A high performance liquid chromatography-electrospray ionization/mass spectrometer (HPLC-ESI/MSn) system was used to analyze the constituents of XFHM granules. An arthritics mouse model was induced by collagen and leflunomide (LEF) was used as a positive control medicine. Pathological changes at the metatarsophalangeal joint were studied through Safranin O and immunohistochemical staining. The differentiation of T, B and NK cells was examined by flow cytometry and pro-inflammatory cytokines were assayed using an Inflammation Antibody Array assay. The expression of key molecules of the nuclear factor κB (NF-κB) and Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathways in spleen were studied by western-blot analysis. In our study. 21 different dominant chemical constituents were identified in XFHM. Treatment with XFHM suppressed the pathological changes in arthrosis of CIA. Additionally, XFHM down-regulated the proliferation and differentiation of CD3+ T cells and CD3−CD19+ B cells significantly. However, XFHM had no significant effect on CD3−NK1.1+ NK cells. Further study showed that the production of pro-inflammatory cytokines had been suppressed by inhibiting the activation of NF-κB and JAK/STAT signaling. XFHM can regulate and maintain the immunologic balance of lymphocytic immunity and inhibit the production of pro-inflammatory cytokines, thus suppressing the pathological changes of RA. Therefore, XFHM may be used as an application of traditional medicine against RA in modern complementary and alternative therapeutics.

14 July 2022 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
SCSisi Chen
Sisi Chen
YLYang Liu
Yang Liu
XOXia Ou
Xia Ou
JLJinyu Li
Jinyu Li
CZCheng-Ting Zi
Cheng-Ting Zi
YLYe Liu
Ye Liu
Background: Nanovaccines have shown the promising potential in controlling and eradicating the threat of infectious diseases worldwide. There has been a great need in developing a versatile strategy to conveniently construct diverse types of nanovaccines and induce potent immune responses. To that end, it is critical for obtaining a potent self-adjuvant platform to assemble with different types of antigens into nanovaccines. Results: In this study, we identified a new natural polysaccharide from the rhizomes of Bletilla striata (PRBS), and used this polysaccharide as a platform to construct diverse types of nanovaccines with potent self-adjuvant property. In the construction process of SARS-CoV-2 nanovaccine, PRBS molecules and RBD protein antigens were assembled into ~ 300 nm nanoparticles by hydrogen bond. For HIV nanovaccine, hydrophobic effect dominantly drove the co-assembly between PRBS molecules and Env expression plasmid into ~ 350 nm nanospheres. Importantly, PRBS can potently activate the behaviors and functions of multiple immune cells such as macrophages, B cells and dendritic cells. Depending on PRBS-mediated immune activation, these self-adjuvant nanovaccines can elicit significantly stronger antigen-specific antibody and cellular responses in vivo, in comparison with their corresponding traditional vaccine forms. Moreover, we also revealed the construction models of PRBS-based nanovaccines by analyzing multiple assembly parameters such as bond energy, bond length and interaction sites. Conclusions: PRBS, a newly-identified natural polysaccharide which can co-assemble with different types of antigens and activate multiple critical immune cells, has presented a great potential as a versatile platform to develop potent self-adjuvant nanovaccines.

30 August 2019 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
KZKe Zuo
Ke Zuo
YQYingying Qi
Yingying Qi
CYCai Yuan
Cai Yuan
Longguang JiangLongguang Jiang
Longguang Jiang
PXPeng Xu
Peng Xu
JLJinyu Li
Jinyu Li

1 April 2020 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
JLJinyu Li
Jinyu Li
TXTaotao Xu
Taotao Xu
WHWenqing Hou
Wenqing Hou
FLFeng Liu
Feng Liu
WQWei Qing
Wei Qing
JWJie Weng
Jie Weng